

ASX RELEASE (18 February 2026)

EPSILON HEALTHCARE LIMITED

Establishment of New Epsilon Biotech Subsidiary

Epsilon Healthcare Limited (ASX: EPN) (“Epsilon” or “the Company”) is pleased to announce the establishment of **Epsilon Biotech**, a new subsidiary created to accelerate the Company’s innovation pipeline and expand its footprint across high value therapeutic & wellness markets.

Epsilon Biotech has been formed as a specialist therapies & formulation development subsidiary, with a mandate to focus on the research, formulation and commercialisation of novel dosage formulations and advanced therapeutic products. While continuing to draw upon Epsilon’s established capabilities within the medicinal cannabis landscape, Epsilon Biotech’s scope will focus beyond cannabis based medicines into broader specialised therapeutics, including innovative drug delivery systems, enhanced bioavailability formulations, and next generation pharmaceutical & therapeutic technologies.

The creation of Epsilon Biotech represents a strategic step in Epsilon’s long term diversification and growth plan, allowing the Company to:

- accelerate the development of proprietary intellectual property;
- strengthen its internal R&D capabilities;
- pursue new partnership and licensing opportunities; and
- diversify its product portfolio into new non-cannabis based high margin therapeutic categories.

Managing Director and Group CEO of Epsilon Healthcare, Peter Giannopoulos said:

“The establishment of Epsilon Biotech marks a significant milestone in our evolution and strongly reaffirms our commitment to innovation, differentiation, and long term value creation. This new subsidiary provides a dedicated and agile platform from which Epsilon can accelerate the development of cutting edge formulations, advanced dosage technologies, and next generation therapeutic solutions. Guided by a clear mandate to challenge the status quo, Epsilon Biotech will enable us to accelerate the advancement of innovative products. This forward looking approach strengthens our ability to anticipate emerging patient needs, meet the evolving expectations of clinicians, and capture new opportunities across medicinal cannabis and the broader specialised therapeutics landscape.”

By harnessing our technical expertise, scientific capability, and visionary approach, Epsilon Biotech positions the Company to lead in the creation of differentiated, high impact therapies that make a meaningful contribution to patient care”.

Epsilon Biotech will commence operations immediately, with its initial development programs already underway. Further updates on product initiatives, partnerships and commercial milestones will be provided as progress continues.

The Board of Epsilon Healthcare believes the creation of Epsilon Biotech positions the Company for meaningful growth and enhanced shareholder value as it evolves into a diversified therapeutic innovator.



ENDS

This announcement has been unanimously approved for release by the Board of Directors.

Alan Beasley
Chairman

For further information, please contact:

Peter Giannopoulos
Group Chief Executive Officer & Managing Director
e: corporate@epsilonhealthcare.com.au



Epsilon Healthcare Limited (ASX: EPN) – epsilonhealthcare.com.au

Epsilon Healthcare Limited (**ASX: EPN**) is an Australian based, globally active healthcare organisation. EPN operates a diversified and vertically integrated portfolio of subsidiary businesses, including healthcare and clinics operations, pharmaceutical contract development and manufacture, pharmacy services and biotechnology products innovation.

For personal use only

